Logo image
Back
Plaque Radiotherapy for Juxtapapillary Choroidal Melanoma Tumor Control in 650 Consecutive Cases
Journal article   Peer reviewed

Plaque Radiotherapy for Juxtapapillary Choroidal Melanoma Tumor Control in 650 Consecutive Cases

Mandeep S. Sagoo, Carol L. Shields, Arman Mashayekhi, Jorge Freire, Jacqueline Emrich, Jay Reiff, Lydia Komarnicky and Jerry A. Shields
Ophthalmology (Rochester, Minn.), v 118(2), pp 402-407
01 Feb 2011
DOI: https://doi.org/10.1016/j.ophtha.2010.06.007
PMID: 20813410
Featured in Collection :   UN Sustainable Development Goals @ Drexel

Abstract

Life Sciences & Biomedicine Ophthalmology Science & Technology
Purpose: To evaluate treatment of juxtapapillary choroidal melanoma with plaque radiotherapy and to investigate the role of supplemental transpupillary thermotherapy (TTT). Design: Retrospective, comparative case series. Participants: We included 650 consecutive eyes with juxtapapillary choroidal melanoma within 1 mm of the optic disc. Methods: Eyes with juxtapapillary choroidal melanoma receiving plaque radiotherapy over a 31-year period from October 1974 to November 2005 were included in the study. The TTT and no TTT groups were analyzed separately and compared. Main Outcome Measures: Local tumor control, metastasis, and tumor-related mortality. Results: The median basal tumor diameter was 10 mm (range, 1.5-21) and median thickness was 3.5 mm (range, 0.5-14.8). In 481 eyes (74%), the tumor was directly adjacent to the optic disc and in 169 eyes (26%) the posterior tumor margin was between 0.1 and 1.0 mm from the optic disc. The circumpapillary extent of the tumor was < 4 clock-hours in 321 eyes (50%), 4-8 clock-hours in 250 eyes (38%), and > 8 clock-hours in 79 eyes (12%). Plaque radiotherapy using iodine-125 in 616 eyes (95%), cobalt-60 in 19 eyes (3%), iridium-192 in 12 eyes (2%), and ruthenium-106 in 3 eyes (< 1%) delivered a median radiation dose of 8000 cGy (range, 3600-15 500) to the tumor apex and adjunctive TTT was used in 307 eyes (56%). Kaplan-Meier estimates for tumor recurrence, metastasis, and death were 14%, 11%, and 4% at 5 years and 21%, 24%, and 9% at 10 years, respectively. Eyes treated with additional TTT showed slight (statistically nonsignificant) reduction in recurrence and metastasis. Using multivariable analysis, factors predictive of tumor recurrence included foveolar tumor requiring TTT (hazard ratio, 5.07; P < 0.001) and greater tumor thickness (hazard ratio, 1.29 per mm increase; P < 0.001). Factors predictive of metastasis included greater tumor base (hazard ratio, 1.21 per mm increase; P < 0.001) and increasing intraocular pressure (hazard ratio, 1.11 per mmHg increase; P = 0.020). Conclusions: Plaque radiotherapy for juxtapapillary melanoma provides local tumor control in approximately 80% of eyes at 10 years. In subjects who received TTT, there was slight but nonsignificant improved local tumor control and lower metastatic rate. Financial Disclosure(s): The authors have no proprietary or commercial interest in any of the materials discussed in this article. Ophthalmology 2011;118:402-407 (C) 2011 by the American Academy of Ophthalmology.

Metrics

6 Record Views
42 citations in Web of Science
55 citations in Scopus

Details

UN Sustainable Development Goals (SDGs)

This publication has contributed to the advancement of the following goals:

#3 Good Health and Well-Being

InCites Highlights

Data related to this publication, from InCites Benchmarking & Analytics tool:

Collaboration types
Domestic collaboration
International collaboration
Web of Science research areas
Ophthalmology
Logo image